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Abstract
Background: Many patients with cystic fibrosis (CF) suffer from allergic disease, which can complicate treatment of CF lung
disease. Interleukin (IL)-4 and IL-13 have been shown to be important mediators in allergic disease. Objective: To investigate the
role of IL-4 and IL-13 in allergic and non-allergic CF patients. Methods: Expression of IL-4 and IL-13 mRNA was investigated
in peripheral blood mononuclear cells (PBM) of seven CF patients with allergy, of six patients without allergy and of nine healthy
subjects as well as in BAL cells of four patients and of all controls. PBM from six patients were incubated with recombinant
human IL-13 or human antiIL-13 antibody without and with LPS stimulation and TNFa levels were measured by ELISA. Results:
IL-13 mRNA expression was increased in allergic and non-allergic patients compared to controls. No significant difference in IL-
4 expression could be found between patients and controls. Addition of IL-13 decreased TNFa in PBM culture supernatants.
Conclusion: Our data suggest that IL-13 rather than IL-4 might play an important role in both allergic and non-allergic CF
patients. IL-13 might also compromise host defence by decreasing TNFa production.
 2003 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
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1. Introduction
Cystic fibrosis (CF) is the most common life short-
ening autosomal recessive disorder in Caucasian people
w1x. The main cause for morbidity and mortality is the
involvement of the lung. Chronic infection and inflam-
mation lead to bronchiectasis and obstructive pulmonary
disease. Many patients also develop allergic diseases
like bronchial asthma and allergic bronchopulmonary
aspergillosis (ABPA): sparsely the mold Aspergillus
fumigatus accelerates pulmonary deterioration w2,3x.
Moreover, approximately 50% of all CF patients have
elevated levels of immunoglobulin E (IgE) in serum
w2x. Allergic disease in CF patients can complicate both
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diagnosis and treatment of infectious exacerbations.
However, the underlying pathomechanisms are far from
being completely understood.
Interleukin-4 (IL-4) and Interleukin-13 (IL-13) are
two cytokines which have been shown to be involved
into pathophysiological reactions in allergic disease by
regulating IgE production by B cells w4,5x. IL-4 is
produced by Th2 lymphocytes which are implicated in
numerous pathophysiological reactions related to aller-
gen responses and eosinophilia w6x. In CF, IL-4 was
described to be involved into the pathogenesis of ABPA
w7,8x. IL-13, a more recently described cytokine is
sharing some biological properties with IL-4 w9x.
We hypothesised that IL-4 and IL-13 might play an
important role in the pathophysiology of allergic reac-
tions in CF patients. Therefore, we sought to investigate
IL-4 and IL-13 expression in allergic and in non-allergic
CF patients.
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2. Patients and methods
Thirteen adult CF patients were investigated (10
patients were homozygous for DF508, no genotyping
was available for the other 3). This group was divided
into two subgroups: allergic patients (ns7) and non-
allergic patients (ns6). Allergy was defined by elevated
serum IgE levels ()100 kUyl), )1 positive skin test
andyor elevated IgE in RAST and a history of allergy.
Pseudomonas aeruginosa was found in sputum culture
of all patients. Three patients received systemic corti-
costeroids (2 allergic, 1 non-allergic). 9 healthy volun-
teers served as control group.
Pulmonary function was measured in all patients but
one and in all control subjects by spirometry, bodypleth-
ysmography (BodyScope, Medizin Electronic GmbH,
Germany) and gas check from capillary blood (Compact
2 Blood Gas Analyzer, AVL, Austria). The forced
expiratory volume in 1 s (FEV1) and the vital capacity
(VC) were selected to describe the status of the lung.
Blood samples of all patients and controls were
obtained for peripheral blood mononuclear cells (PBM).
Total immunoglobulin E (IgE) and specific IgE to
common allergens was determined using the Unicap 100
system (Pharmacia, Uppsala, Sweden).
After informed consent was obtained four patients
and all control subjects underwent fiberoptic bronchos-
copy. Bronchoalveolar lavage was performed by instill-
ing 160 ml of sterile 0.9% saline solution in 20
ml-aliquots into the middle lobe and by withdrawing
the fluid immediately.
2.1. Cell isolation and RNA preparation
Peripheral blood mononuclear cells (PBM) were iso-
lated by centrifugation over Ficoll-Paque (Pharmacia,
Uppsala, Sweden) and washed twice with PBS contain-
ing 2% fetal calf serum (Seromed, Berlin, Germany).
Cells of the bronchoalveolar lavage (BAL) were isolated
by centrifugation and washed once with PBS containing
2% fetal calf serum. RNAzol (Wak, Bad Soden, Ger-
many) was added and samples were stored at y20 8C
until further preparation. RNA was extracted by treat-
ment with chloroforme and precipitated with
isopropanol.
2.2. RT-PCR
RNA was reverse-transcribed using 2 ml 25 mM
MgCl , 1 ml 10=PCR Buffer, 1 ml 10 mM of each2
deoxynucleotide triphosphate (dNTP), 0.5 ml 50 mM
OligodT, 0.5 ml 20 Uyml RNAse inhibitor and 0.5 ml
50 Uyml reverse transcriptase (Perkin Elmer Biosys-
tems, Roche, Branchburg, USA). The mixture was
incubated at 42 8C for 30 min and at 99 8C for 5 min.
Samples were stored at y20 8C until amplification.
The resultant cDNA was amplified by PCR in a
thermal cycler (Hybaid, Teddington, UK) with a final
volume of 100 ml containing 10 ml cDNA (IL-13, IL-
4) or 5 ml cDNA (b-actin), 10 ml or 15 ml dilution
buffer, 8 ml 12 mM MgCl , 8 ml 10=PCR buffer, 55.52
ml H O with DEPC, 0.5 ml 5 Uyml recombinant Taq2
DNA polymerase (Perkin Elmer Biosystems, Roche,
Branchburg, USA) and 2.0 ml 15 mmol of each primer.
The oligonucleotide primers for PCR were based on
published mRNA sequences. The b-actin served as
control. The human b-actin primers were 59-GTG GGG
CGC CCC AGG CAC CA-39 for the upstream primer
and 59-CTC CTT AAT GTC ACG CAC GAT TTC-39
for the downstream primer; IL-13 utilized 59-GAG TGT
GTT TGT CAC CGT TG-39 for the upstream primer
and 59-TAC TCG TTG GTC GAG AGC TG-39 for the
downstream primer. IL-4 primers were 59-GGA CAC
AAG TGC GAT ATC ACC-39 for the upstream primer
and 59-ATT TCT CTC TCA TGA TCG TC-39 for the
downstream primer. PCR amplification for b-actin was
performed for 36 cycles (1 min at 94 8C, 1 min at 60
8C, 40 s at 72 8C), for 35 cycles (45 s at 95 8C, 45 s
at 60 8C, 90 s at 72 8C) for IL-13 and for 38 cycles (1
min at 95 8C, 1 min at 60 8C, 1 min at 72 8C) for IL-
4.
2.3. Identification of PCR products
PCR products were analysed by electrophoresis on a
2% agarose gel containing ethidium bromide and visu-
alized by UV light. The sizes of the PCR products were
compared with the expected PCR product length and
molecular weight markers (Boehringer, Mannheim,
Germany).
2.4. Recombinant human Interleukin-13 and anti-Inter-
leukin-13
Recombinant human IL-13 (rhIL-13) was used at a
concentration of 5 ngyml as indicated by the manufac-
turer (R and D Systems, Minneapolis, USA). Mono-
clonal anti-human IL-13 (antiIL-13) concentration was
2 mgyml to inhibit IL-13 activity as indicated by the
manufacturer (R and D Systems, Minneapolis, USA).
2.5. Tumor necrosis factor a enzyme-linked immuno-
absorbent assay (ELISA)
A tumor necrosis factor a (TNFa) ELISA (R and D
Systems, Minneapolis, USA) was used to determine the
concentration of TNFa in cell culture supernatants of
PBM after 18 h of incubation in a group of six patients
with and without stimulation by 0.2 mgyml lipopolysac-
charide (LPS) (for the whole time of incubation) and
addition of rhIL-13 or antiIL-13. TNFa concentrations
were determined by comparison with recombinant stan-
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Table 1
Characteristics of patients and controls
Allergic CF Non-allergic CF Controls Pˆ
Number 7 6 9
Median age (years) 25.0 28.5 27.4
Malesyfemales 3y4 3y3 4y5
IgE (kUyl)* 400.5"23.9 61.2"21.4 30.8"12.6 -0.05y-0.05yn.s.
FEV1 (%)* 42.3"5.5 46.5"7.9 98.6"1.6 n.s.y-0.05y-0.05
VC (%)* 52.4"5.9 53.6"7.4 96.9"1.8 n.s.y-0.05y-0.05
*Mean"S.E.M. ˆP values of allergic vs. non-allergicyallergic vs. controlynon-allergic vs. control. n.s: not significant.
Table 2
PBM and BAL cell counts
Allergic CF patients Non-allergic CF patients Controls
PBM total (=10 yml)6 13.9"2.4 10.8"2.1 9.8"1.6
Monocytes (%) 37.9"7.5 36.8"6.4 32.4"1.1
Lymphocytes (%) 27.4"5.9 26.7"6.2 41.7"3.6
Neutrophils (%) 34.5"9.2 36.3"6.6 25.8"4.4
Eosinophils (%) 0.2"0.1 0.2"0.1 0.1"0.1
BAL total (=10 yml)6 23.4"13.3 45.4* 3.9"0.6
Alveolar macrophages (%) 6.8"3.2 9* 84.5"2.1
Lymphocytes (%) 1.7"0.4 1* 10.2"1.8
Neutrophils (%) 91.3"3.7 90* 5.2"1.6
Eosinophils (%) 0.2"0.2 0* 0.1"0.1
Mean"S.E.M. *: Only one BAL sample could be investigated.
dards rum parallel with each batch of assay. Minimum
detectable dose of TNFa was less than 4.4 pgyml as
indicated by the manufacturer.
2.6. PBM cell culture
PBM were cultured in RPMI medium (Biochrom KG,
Berlin, Germany) containing 10% FCS, 1% L-glutamine
and 2% penicillineystreptomycine. Temperature was
37.0 8C. Atmosphere contained 5.0% CO . Incubation2
time was 18 h. Cell culture supernatants for ELISA
measurements were obtained by centrifugation (3.000
rev.ymin, 10 min).
2.7. Statistics
Mean values of the data were compared by Mann–
Whitney test. A P value -0.05 was considered
significant.
3. Results
3.1. IgE serum protein levels, FEV1 and VC
IgE serum protein, FEV1 and VC mean values are
shown in Table 1. IgE serum levels were significantly
increased in allergic patients in comparison to non-
allergic patients and controls (P-0.05) whereas IgE
serum protein levels were not statistically different
between non-allergic patients and controls.
3.2. PBM and BAL cell counts
There was no significant difference in PBM total as
well as differential cell counts between both patient
groups. PBM and BAL cell counts for patients and
controls are shown in Table 2.
3.3. Expression of IL-13 mRNA
PBM of all patients showed IL-13 expression. In
contrast, IL-13 mRNA was virtually absent in PBM of
normal control subjects. IL-13 mRNA expression could
be detected in all of the investigated samples of BAL
cells in CF patients (Fig. 1). In control subjects, IL-13
expression could only be detected in two BAL samples
in very low amounts.
3.4. Expression of IL-4 mRNA
In PBM IL-4 mRNA was expressed in all patients
and all but one of the tested control persons. IL-4
mRNA expression could neither be detected in BAL
cells of CF patients nor in the healthy control subjects
(Fig. 2).
3.5. Effect of stimulation of PBM with rhIL-13 on TNFa
production
Protein concentrations of TNFa in cell culture super-
natants of PBM after 18 h of incubation were determined
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Fig. 1. RT-PCR of IL-13 mRNA expression in BAL cells and PBM of patients and controls. Lanes 1–8: b-actin in BAL cells (1,2) and PBM
(3,4) of two patients and in BAL cells (5,6) and PBM (7,8) of two control persons as internal standard. Lanes 9–16: IL-13 is expressed in BAL
cells (9,10) and PBM (11,12) of the patients but only in low amounts in BAL cells (13,14) and PBM (15,16) of the control persons. Lenght of
IL-13 transcript was 275 bp as expected. M: molecular weight marker.
by ELISA in samples of six patients. RhIL-13 and
antiIL-13 were utilised with and without LPS stimulation
(Fig. 3). TNFa protein concentrations were
20.69"11.76 pgyml after 18 h of incubation and
increased to 760.82"471.40 pgyml after stimulation
with LPS. RhIL-13 decreased TNFa levels to
16.25"6.11 pgyml without (P)0.05; not significant)
and 259.07"219.79 pgyml after stimulation (P-0.05).
After adding antiIL-13, TNFa concentrations were
increased without (43.69"26.96 pgyml; P-0.05) and
with stimulation by LPS (818.15"445.73 pgyml; not
significant) (Fig. 3).
4. Discussion
In the present study increased IL-13 mRNA expres-
sion in PBM of CF patients could be demonstrated in
both allergic and non-allergic patients in comparison to
healthy non-allergic subjects. Moreover, analysis of BAL
cells revealed increased IL-13 expression in allergic and
non-allergic patients and only small expression in the
control group. However, there was no significant differ-
ence in IL-4 expression in PBM between patient groups
and the control group. No IL-4 mRNA expression was
found in BAL cells of patients or controls.
These findings indicate that IL-13 might play a more
important role in CF than IL-4. Moser et al. reported a
Th2 predominated immune response in CF patients
chronically infected with Pseudomonas aeruginosa w10x.
In that study increased secretion of IL-4 from PBM after
stimulation was found. Although we found Pseudomon-
as aeruginosa in sputum cultures of all patients we did
not observe increased IL-4 expression compared to
control subjects. However, we investigated non-stimu-
lated cells.
In our study, there was a significant difference in IL-
13 expression between allergic and non-allergic patients
compared to control subjects. This suggests that IL-13
might be involved in both allergic and non-allergic
processes in CF. However, from these data it is not clear
whether IL-13 might be more important in mediating
allergic reactions in CF than being a typical mediator in
chronic Pseudomonas aeruginosa infection.
IL-13 might alter directly or indirectly (via induction
of other mediators) the lung function in CF patients. It
might be also responsible for bronchial hyperresponsi-
veness, which is a common symptom in CF patients.
Since IL-13 expression could be demonstrated in BAL
cells it might also act as a local mediator similar to its
role in asthma. However, the number of patients in this
study was too small to draw any conclusions.
PBM of CF patients may be a major source of IL-13
production in peripheral blood. IL-13 is known to be
mainly produced by CD4q T helper cells w11x and
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Fig. 2. RT-PCR of IL-4 mRNA expression in BAL cells and PBM of patients and control persons. Lanes 1–8: b-actin in BAL cells (1,2) and
PBM (3,4) of two patients and in BAL cells (5,6) and PBM (7,8) of two control persons as internal standard. Lanes 9–16: IL-4 is expressed in
PBM of the patients (11,12) and the control persons (15,16) but not in BAL cells of the patients (9,10) or the control persons (13,14). Lenght
of IL-4 transcript was 399 bp as expected. M: molecular weight marker.
Fig. 3. TNFa protein concentrations in PBM cell culture supernatants. Columns indicate mean values after 18 h of incubation (20.69 pgyml,
control) with rhIL-13 (16.25 pgyml) and antiIL-13 (43.69 pgyml) and after stimulation using LPS (760.82 pgyml, control) with rhIL-13 (259.07
pgyml) and antiIL-13 (818.15 pgyml). *: P-0.05 vs. control.
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patients had considerable proportions of lymphocytes
(27.0 and 26.2%) in PBM.
IL-13 has been reported to have powerful antiinflam-
matory activities w12x. This might be important in CF
in terms of decreasing the host defence against bacterial
infections e.g. Pseudomonas aeruginosa. Therefore, we
investigated the effect of IL-13 on PBM of CF patients.
RhIL-13 and antiIL-13 were applied on unstimulated
and stimulated PBM and TNFa production was meas-
ured. RhIL-13 administration decreased TNFa produc-
tion in both stimulated and unstimulated PBM. After
blocking the effect of IL-13 by using antiIL-13, TNFa
production was increased. These data suggest that IL-13
might be involved in regulation of TNFa production in
PBM of CF patients. Our data correspond to the results
of Cosentino et al. who described a reduction of TNFa
secretion of monocytes after IL-13 stimulation w13x. IL-
13 might decrease TNFa secretion from PBM in CF
thus worsening host defence in case of bacterial infec-
tion. The increase of TNFa protein in supernatants in
the presence of antiIL-13 antibodies in comparison to
without further supports the notion that IL-13 is endog-
enously expressed and secreted by PBM in CF.
5. Conclusion
IL-13 but not IL-4 expression was increased in CF
patients with and without allergy. IL-13 could also be
shown to decrease TNFa production from PBM. These
results suggest that IL-13 might have antiinflammatory
effects in CF patients thus compromising host’s defence.
Further studies are warranted to study the effects of IL-
13 on the lung in CF patients. IL-13 might also be an
interesting candidate for a mediator of bronchial hyper-
responsiveness in CF.
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